1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The LCRP CEA mechanism was first offered in FY13. Since then, 35 CEA applications have been received, and 5 have been recommended for funding. This award mechanism supports early-phase, proof-of-principle clinical trials and correlative studies to investigate hypothesis-based, innovative interventions that have the potential to resolve current clinical barriers and result in a profound impact on the clinical management of lung cancer. While therapeutic approaches proposed for testing through the CEA must represent novel, hypothesis-based, “outside-the-box” approaches for treating lung cancer, they may include therapies already in clinical use, or undergoing clinical testing for other diseases, provided that the proposed use for lung cancer would lead to a major advancement for treating the disease. Outcomes from studies funded by this award are anticipated to provide scientific rationale for subsequent development of larger, efficacy-based clinical trials of interventions that will transform lung cancer clinical care. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Clinical Trials Category: The CEA supports clinical trials encompassing Phase 0, Phase I, or pilot Phase II for drug or drug combinations, Class II or III devices, or other types of trials that conduct early clinical testing of innovative approaches for lung cancer. Information on clinical trials and phases/classes of study is provided in the “Human Subject Resource Document” available for download from eBRAP at https://ebrap.org/eBRAP/public/Program.htm. Correlative Studies Category: The CEA-Correlative Studies category supports innovative, hypothesis-based, correlative studies that derive from ongoing or completed clinical trials supported by other funding sources. These correlative studies, if successful, will have the potential to significantly inform treatment strategies, identify subsets of patients for treatment with specific therapies, provide increased understanding of biological changes resulting from the intervention in lung cancer, or provide other insight that will significantly enhance clinical management of lung cancer. Examples of correlative studies appropriate for submission to the CEA-Correlative Studies category may include, but are not limited to: • Analysis of biomarkers for prognosis and/or prediction or assessment of therapeutic response or progression • Investigations of the mechanism of action or the development of resistance to a drug • Analysis of immune response or factors associated with progression • Characterization of tumor antigens for the development of new improved therapies
Funding Opportunity Number: W81XWH-15-LCRP-CEA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $2.2M total program funding.
Get alerted about grants like this
Save a search for “Dept. of the Army -- USAMRAA” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $2.2M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 16, 2015, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — DoD Lung Cancer Clinical Exploration Award is offered by Dept. of the Army -- USAMRAA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Alzheimer's Research Program (AZRP) Transforming Care Award (TrCA) is sponsored by Dept. of the Army -- USAMRAA (Congressionally Directed Medical Research Programs - CDMRP). The fiscal year 2026 (FY26) Alzheimer's Research Program (AZRP) Transforming Care Award (TrCA) supports clinical research or clinical trials evaluating interventions, innovations, and solutions in critical areas for dementia care for individuals with Alzheimer's disease and Alzh…
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Era of Hope Scholar Award supports individuals who are early in their careers with significant potential to effect meaningful change in breast cancer. As the Intent of the FY26 BCRP Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the award’s central features include the Principal Investigator’s (PI’s) demonstrated ability to go beyond conventional thinking in their field and the innovative and meaningful contributions that they can make toward ending breast cancer. The Era of Hope Scholar Award requires exceptionally talented scientists that are among “the best and the brightest” in their field(s), with demonstrated experience forming effective partnerships and collaborations and strong potential for future leadership in breast cancer research. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· The PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award.· The research team must include two or more breast cancer consumer advocates. Funding Opportunity Number: HT942526BCRPEOHS. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $4.9M total program funding.
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.Distinctive Features:· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA. Funding Opportunity Number: HT942526BCRPTBCCDA. Assistance Listing: 12.420. Funding Instrument: CA. Category: ST. Award Amount: $140K total program funding.